The purpose of this study was to evaluate the toxicity and efficacy of high-dose busulfan, melphalan and thiotepa (Bu/Mel/TT) in patients with high-risk noninflammatory breast cancer defined as stage II disease у10 lymph nodes (n = 52) or stage III (n = 69), and prognostic factors for treatment outcome. 1-9 At 5 years, the best reported relapsefree survival for patients with four to nine metastatic lymph nodes is 46-67%; 1 at 10 years, 32-47%. 2 Moreover, the risk of relapse increases with each additional metastatic lymph node found at surgery. Patients with stage II breast cancer who have у10 lymph-nodes containing metastatic
Despite adjuvant chemotherapy at conventional doses, patients with breast cancer who are stage II with Ͼ3 positive axillary lymph nodes or stage III at diagnosis have a high risk of relapse. [1] [2] [3] [4] [5] [6] [7] [8] [9] At 5 years, the best reported relapsefree survival for patients with four to nine metastatic lymph nodes is 46-67%; 1 at 10 years, 32-47%. 2 Moreover, the risk of relapse increases with each additional metastatic lymph node found at surgery. Patients with stage II breast cancer who have у10 lymph-nodes containing metastatic disease, [3] [4] [5] [6] [7] and stage III disease 8, 9 have a probability of disease-free survival (DFS) at 5 years of 13 to 45% which falls to 10 to 30% at 10 years.
The experimental and clinical observations suggesting a significant dose-response relationship in metastatic and primary breast cancer [10] [11] [12] [13] [14] have encouraged the evaluation of high-dose chemotherapy supported with autologous stem cell infusion (HDC/ASCI) as treatment for breast cancer. While a wide range of regimens and trials have evaluated this approach in metastatic disease, relatively few trials have investigated the therapeutic potential of HDC/ASCI in high-risk non-inflammatory breast cancer. [15] [16] [17] [18] [19] [20] [21] [22] The use of STAMP-I (cyclophosphamide, carmustine and cisplatin), 15 STAMP-V (cyclophosphamide, thiotepa and carboplatin), [18] [19] [20] [21] CAVP/CCVP (cyclophosphamide, etoposide and either cisplatin or doxorubicin) 16 and CEP (cyclophosphamide, etoposide and cisplatin) 22 has resulted in event-free survival (EFS) probabilities ranging from 0.48 to 0.72 at 3.5 years after diagnosis 16, 17, 19, 21 or from the first day of adjuvant chemotherapy 15, 18, 20, 22 in patients with high-risk non-inflammatory breast cancer.
Studies carried out at the Fred Hutchinson Cancer Research Center (FHCRC) have evaluated a regimen of busulfan, melphalan and thiotepa, three drugs with observed activity in patients with hematologic malignancies and patients with breast cancer. The rationale for use of this regimen is based on the recognized activity of melphalan and thiotepa as single agents in the treatment of breast cancer and the cytotoxic effect observed in metastatic breast cancer when high doses of busulfan are combined with cyclophosphamide. [23] [24] [25] The busulfan, melphalan and thiotepa regimen has shown high activity in the treatment of patients with metastatic breast cancer. [23] [24] [25] Bensinger et al 25 reported estimated probabilities of EFS at 1.5 years for patients with metastatic responsive and refractory disease as 0.53 and 0.24, respectively, with this regimen. The aim of this study was to evaluate the toxicity and efficacy of this regimen in patients with high-risk noninflammatory breast cancer, as well as to identify the prognostic factors which could influence treatment outcome.
Patients and methods
After obtaining written informed consent, patients were treated at the FHCRC, the University of Washington or at hospitals affiliated with the Puget Sound Oncology Consortium (PSOC) according to Institutional Review Board approved protocols of the hospitals where the treatment was administered. Fifty patients were treated at the FHCRC and 71 in member hospitals of PSOC listed in the Appendix. The date of the last follow-up for patients in the present report was 21 July 1999.
Between September 1993 and July 1997, 121 women with high-risk non-inflammatory breast cancer, defined as stage II у10 axillary lymph nodes (n = 52), stage IIIA (n = 62) or stage IIIB (n = 7), 26 were treated with high-dose busulfan, melphalan and thiotepa. Patients with stage IIIB inflammatory carcinoma were excluded from this analysis. Eligibility criteria included age less than 65 years, adequate pulmonary, cardiac, hepatic and renal function and Karnofsky score Ͼ70. Hepatitis B surface antigen (HbsAg) and human immunodeficiency virus serologically positive patients were excluded. Staging studies included computed tomography (CT) of chest and abdomen, bone scan and bone marrow aspirations and biopsies. Cranial CT or magnetic resonance imaging (MRI) of the head was performed if clinically indicated. Patients with stage II disease underwent modified radical mastectomy or lumpectomy followed by standard-dose doxorubicin-based adjuvant chemotherapy prior to HDC/ASCI. Initial treatment for patients with stage III disease was determined by clinical criteria of operable or inoperable tumors according to Haagensen's classification. 27 Patients with stage III disease diagnosed as having operable tumors were initially treated with surgery, followed by standard-dose doxorubicin-based adjuvant chemotherapy. Patients with stage III disease who had inoperable tumors received neoadjuvant chemotherapy followed by surgery. In this study, patients with stage III disease were classified into two groups based on conventional chemotherapy administered following surgery (adjuvant chemotherapy group) or as initial treatment prior to surgery (neoadjuvant chemotherapy group).
Patient characteristics
Patient characteristics are shown in Table 1 . Sixty and 71% of patients with stage II and stage III disease were younger than 50 years, respectively. The main differences between patients with stage III disease beside the initial treatment received were in the hormone receptor and lymph node status. Forty-eight (70%) patients with stage III disease had operable tumors and underwent modified radical mastectomy (n = 47) or lumpectomy (n = 1). Twenty-one (30%) patients were diagnosed as having inoperable tumors, and after diagnostic biopsy, were treated with standard-dose doxorubicin-based induction chemotherapy. Twenty-four (50%) patients of the adjuvant group were ER and PR hormone receptor positive compared to six (29%) patients of the neoadjuvant group, while 12 (20%) and eight (38%) patients were hormone receptor negative, respectively. The median number of metastatic lymph nodes for patients who received adjuvant chemotherapy after surgery was 11 (range 0-35) and five (range 1-18) for those treated with neoadjuvant chemotherapy prior to surgery. The median time between diagnosis and HDC/ASCI for the entire group was 7 months (range [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] .
Treatment prior to transplantation is shown in Table 2 . Modified radical mastectomy was performed in 87% of patients. One of the patients with stage III disease had a history of idiopathic leukopenia. After mastectomy, she was not given adjuvant chemotherapy or radiotherapy and was referred directly for HDC/ASCI using PBSC mobilized with recombinant human granulocyte colony-stimulating factor (G-CSF) alone. Because this patient was diagnosed as having an operable tumor, she has been analyzed with the remaining 47 (68%) patients who received standarddose doxorubicin-based adjuvant chemotherapy following surgery. The combination of cyclophosphamide and adriamycin, with or without 5-fluorouracil, was the adjuvant chemotherapy regimen used in 77 and 87% of patients with stage II and stage III disease, respectively. The median number of cycles administered was four, including those patients treated with neoadjuvant chemotherapy. Residual primary tumor was found in 20 of 21 patients receiving neoadjuvant chemotherapy. Six of the 21 patients received at least two cycles of consolidation chemotherapy after mastectomy with combinations of doxorubicin, taxol or cisplatin. Fifteen patients with residual tumor after mastectomy did not receive consolidation chemotherapy. Fourteen of these were referred directly for PBSC mobilization receiving one cycle of cyclophosphamide and taxol while one patient was mobilized with growth factor alone before HDC/ASCI therapy. Nineteen percent of all patients received radiation therapy prior to transplantation. Patients received HDC followed by infusion of autologous peripheral blood stem cells (PBSC) (n = 119), bone marrow and PBSC (n = 1) or syngeneic PBSC (n = 1).
PBSC mobilization
PBSC were collected after the administration of G-CSF alone, or after the administration of chemotherapy using CY alone (4 g/m (Table 3) . PBSC collection and cryopreservation was performed as previously described.
28,29

High-dose chemotherapy
No chemotherapy was given 4 weeks prior to the start of the conditioning regimen. Twenty-four hours prior to the administration of Bu, patients received phenytoin before the first dose of Bu and continuing until 24 h after the final CSF = colony-stimulating factor; ANC = absolute neutrophil count; CY = cyclophosphamide; T = taxol; A = doxorubicin; E = etoposide; P = cisplatin. . PBSC were thawed and infused 48 h after the last dose of thiotepa using previously published techniques. 28, 29 After the administration of HDC, all patients received prophylactic fluconazole. Prophylactic acyclovir was administered to patients serologically positive for Herpes simplex virus. Prophylactic antibiotics were given when the absolute neutrophil count (ANC) was Ͻ0.5 × 10 9 /l. G-CSF was administered at a dose of 5 g/kg/day after transplantation and was continued until engraftment at the discretion of the attending physicians (n = 30).
Post-transplant treatment
Complete blood counts were measured daily until patients had a white blood cell count Ͼ2 × 10 9 /l and self-supporting platelets Ͼ20 × 10 9 /l. Local chest wall and axillary node radiotherapy was planned for all patients (n = 98) who did not receive radiation prior to transplantation. Eight patients did not receive post-transplant radiation therapy either due to regimen/transplant-related toxicity (stage II n = 4, stage III n = 1) or refusal (stage II n = 1, stage III n = 2). Tamoxifen 20 mg p.o. daily for 5 years was given to all patients with estrogen and/or progesterone receptor positive tumors. Restaging with CT and bone scan or total body MRI was performed at 1-year post transplant, and thereafter according to clinical indications.
Toxicity was evaluated during the first 100 days using the Bearman scale. 30 
Statistical analysis
Univariate comparisons of proportions were made using a Fisher's test. A Cox regression analysis was performed using the SAS system. 31, 32 Probabilities of survival and EFS were estimated from day 0 to the day of last contact and from day 0 to the date of death or relapse censored by the date of last contact according to the method of KaplanMeier. 33 Log-rank test was used to compare survival curves. Table 3 shows the proportion of patients who had PBSC mobilized either with growth factor alone or with chemotherapy, the numbers of stem cells infused after HDC and engraftment results. The median number of CD34 + cells/kg infused was 7.59 × 10 6 . Engraftment, defined as the first of 3 consecutive days on which the ANC was Ͼ0.5 × 10 9 /l occurred in a median of 11 days (range [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] . Platelet engraftment, defined as the first day with 20 × 10 9 /l unsupported for Ͼ7 days, was achieved in a median of 10 days (range 5-46).
Results
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Toxicity Regimen-related toxicity is shown in Table 4 . 30 The chemotherapy regimen was generally well tolerated. Eighty-six percent of patients developed stomatitis grade II-III. Sixteen percent of the patients had gastrointestinal toxicity grade II-III, while grade II skin toxicity was observed in 10% of the patients. Hepatic toxicity grade II was observed in 2% of the patients. Pulmonary toxicity was the most frequent grade IV toxicity observed. There were five deaths due to regimen-related toxicity within 100 days of transplantation. Three patients died on days 21, 34 and 61 secondary to pulmonary toxicity. One patient developed acute respiratory distress syndrome and in the other two patients pathology showed diffuse alveolar damage, mild interstitial inflammation, and alveolar cell dysplasia consistent with drug-induced injury. One patient died secondary to hepatic veno-occlusive disease at day 37 after ASCI infusion. At day 8 post transplant a 43-year-old patient with an unremarkable past medical history developed a sudden cardiac arrest. The etiology, however, could not be determined from anatomic findings at autopsy. Since the onset of the terminal event was abrupt, cardiac toxicity was clinically suspected as the cause of death. Finally, two more patients died on days 165 and 196 secondary to an idiopathic pneumonia syndrome and diffuse interstitial fibrosis, consistent with Bu toxicity, respectively. Overall, transplant-related mortality was 6%. Twenty-five patients (20%) developed documented bacterial or fungal infections, but there were no deaths.
Outcome (Table 5) Stage II: Forty-four of 52 patients (85%) are alive with 37 (71%) in continued remission at a median of 36 months (range 18-64) follow-up. Four patients are not evaluable for relapse due to transplant-related death. Eleven patients (21%) have relapsed. Three relapses were local or nodal recurrences at 6, 8 and 32 months after transplantation. These patients were treated with local excision and/or radiation therapy and tamoxifen and have not progressed. Two patients developed contralateral infiltrative ductal carcinoma 9 and 24 months after HDC/ASCI therapy. They were treated with mastectomy and adjuvant chemotherapy and remain disease-free. Six patients have developed meta- Table 4 Regimen-related toxicity Values given are number of patients (%). Years after transplantation Figure 1 Kaplan-Meier event-free survival for stage II disease (ȦȦ) and stage III disease (--) breast cancer patients treated with high-dose busulfan, melphalan and thiotepa followed by autologous stem cell infusion.
with a follow-up of 30 and 20 months, the remaining patients have died. In one more patient, a contralateral ductal carcinoma was diagnosed 29 months after transplantation. She is without evidence of disease again after treatment with surgery and chemotherapy. 
Prognostic factor analysis
Clinical variables were analyzed to determine effect on outcome. The influences of age, stage of disease, hormone Years after transplantation Figure 2 Kaplan-Meier event-free survival analysis of patients with stage III disease breast cancer treated with HDC/ASCI according to initial treatment with surgery followed by adjuvant chemotherapy (ȦȦ) or neoadjuvant chemotherapy (--) followed by surgery. 
Discussion
In the current study 121 patients with high-risk noninflammatory breast cancer were treated with high-dose Bu, melphalan and thiotepa followed by ASCI. Transplantrelated mortality with this regimen was 6%, higher than STAMP-V, 18-21 CEP 22 and CAVP/CCVP, 16 but lower than STAMP-I. 15 Seventy-eight (64%) patients remain alive in continued remission at a median follow-up of 3 years from transplant (range 1.5-5.3). The probabilities of event-free survival at 3 and 5 years are, 0.62 and 0.60 which is comparable to other high-dose chemotherapy regimens administered in this setting.
Standard-dose chemotherapy has only a modest impact on DFS for patients with high-risk breast cancer. Highdose chemotherapy studies are designed to evaluate the potential improvement in these survival figures. The role of HDC and stem cell transplantation has been evaluated more extensively in metastatic breast cancer, but few phase II trials have studied the therapeutic benefit of this aggressive treatment strategy in patients with high-risk noninflammatory disease. Table 6 summarizes the principal features of the reported clinical trials which include 30 or more patients with stage II (у10 lymph nodes) and stage III non-inflammatory breast cancer patients with a minimal follow-up of 2 years. [15] [16] [17] [18] [19] [20] [21] [22] Two treatment strategies have been evaluated in these trials: HDC/ASCI either as consolidation therapy after initial conventional dose therapy 15, 16, [18] [19] [20] [21] [22] or as first-line therapy. 17 As shown in Table 6 , 616 high-risk non-inflammatory breast cancer patients with a median age of 44 years have been treated in phase II trials. Five randomized phase II clinical trials which compared HDC/ASCI to standard-dose adjuvant chemotherapy have been conducted in this setting. 20, 22, [34] [35] [36] One of the five randomized trials reported have evaluated HDC/ASCI as first-line therapy. 36 However, an on-site review of that trial did not confirm the validity of the study. 37 Two published studies included 41 20 and 39 patients. 22 With a median follow-up from 24 to 78 months, the probabilities of EFS for all patients treated range between 0.48 and 0.72. EFS estimates for stage II are 0.71 and 0.52 to 0.57 for stage III patients, respectively. The Table 6 Selected clinical trials in high-risk non-inflammatory breast cancer according to the number of patients evaluated The median follow-up reported for the majority of phase II trials in high-risk breast cancer is greater than 3 years (24-78 months) from diagnosis 16, 17, 19, 21 or from the first day of adjuvant chemotherapy. 15, 18, 20, 22 An important difference in our study in comparison with those previously reported [15] [16] [17] [18] [19] [20] [21] [22] is the method of calculating survival and EFS. Because this study is focused on the impact of transplantation as consolidation of adjuvant treatment on disease, rather than evaluating the influence on outcomes achieved by a specific adjuvant chemotherapy regimen followed by HDC/ASCI, the survival and EFS have been calculated from the date of transplant, rather than from the date of diagnosis or start of adjuvant chemotherapy. This method excludes the period of time prior to transplantation and thus eliminates the bias generated when the time origin is calculated from diagnosis/start of chemotherapy. 39 This period of time ranges from 3 to 6.5 months in the studies reported. 15, 16, [18] [19] [20] [21] [22] The best high-dose chemotherapy regimen for the treatment of high-risk non-inflammatory disease is unknown, but most current regimens are less toxic than the initial regimen of CY, cisplatin and carmustine (STAMP-I) which produced a 12% mortality. 15 With greater experience, mortality from the STAMP I regimen has been reduced to 8%. 34 The mortality of STAMP-V, 40 a regimen based on CY, thiotepa and carboplatin and used in the majority of patients with high-risk non-inflammatory breast cancer, is less than 1%. [18] [19] [20] [21] Other regimens have included the combination of CY, etoposide, and either doxorubicin or cisplatin (CAVP/CCVP) 16 or (CEP) 22 reporting a mortality between 3% 22 and Ͻ1%. 16 The Bu/Mel/TT regimen reported here was developed because of the demonstrated activity of the individual drugs in breast cancer and the ability to significantly dose-escalate the drug in this regimen with the use of stem cell support. Toxicity secondary to Bu/Mel/TT regimen has been described previously. [23] [24] [25] 41, 42 Mucositis is the most common grade I-II toxicity and has been observed in 80% to 100% of patients, while the main grade III/IV toxicities are gastrointestinal, hepatic, cardiac, and pulmonary ranging from 2% to 6%. In the current study, grade I-II gastrointestinal toxicity was the most frequent nonhematological toxicity observed and there were five deaths (4%) within 100 days secondary to pulmonary, hepatic and cardiac toxicities. Two more deaths (2%) occurred on days 165 and 196. Thus, in spite of comparable efficacy of Bu/Mel/TT with other regimens evaluated for high-risk non inflammatory breast cancer, the 6% transplant-related mortality reported in this study is the main disadvantage of this regimen compared to STAMP-V or CAVP/CCVP. However, this death rate could be over-represented. A pretreatment history analysis showed that four of seven patients who died could be at highest risk for developing transplant/regimen-related mortality. In the absence of a remarkable past medical history, age may be an important risk factor for regimen-related toxicity. Two of the three patients included in this study who were older than 60 years died secondary to pulmonary toxicity and hepatic venoocclusive disease. Two patients died after 100 days, one who was cytomegalovirus positive pretransplant and one with a significant history of smoking who died of diffuse pulmonary fibrosis. Since the efficacy of Bu/Mel/TT regimen is comparable to other regimens evaluated, efforts to diminish the toxicity of this regimen are warranted. Studies to diminish hepatic and pulmonary toxicities could be designed taking advantage of the availability of intravenous Bu, which could diminish interpatient variability of oral absorption. Bu i.v. administered by continuous infusion over 3-4 days to eliminate peak concentrations is another approach which could be evaluated. 43 Novel agents such as IL-11 or keratinocyte growth factor warrant further evaluation to reduce oral and gastrointestinal toxicities. Moreover, if further follow-up corroborates the effectiveness of Bu/Mel/TT regimen in stage II disease, the aim of future studies should be to decrease toxicity without loss of effectiveness.
Prognostic factors associated with an adverse outcome in the high-risk non-inflammatory disease treated with HDC/ASCI have been evaluated in two trials. 16 , 21 Somlo et al 16 have identified progesterone receptor negativity and high-grade tumors in the high-risk non-inflammatory setting as adverse prognostic factors. By univariate analysis, age Ͻ45, estrogen/progesterone negativity, N2 stage, and locally advanced breast cancer were identified as adverse prognostic factors in a series of 92 patients reported by Schwartzberg et al. 21 In that study all patients were treated with surgery followed by adjuvant chemotherapy prior to transplantation. The 24 patients with stage III locally advanced disease had the poorest survival, and the probability of EFS at 4 years for this group of patients was 0.37. The multivariate analysis confirmed that ER negative patients and patients with advanced disease had a poor outcome. Our study included 69 patients with stage III disease, 48 (70%) of whom were treated with surgery followed by adjuvant chemotherapy and 21 (30%) patients who had inoperable tumors were treated initially with neoadjuvant chemotherapy followed by surgery. The probability of EFS at 3 and 5 years for the group of patients treated with adjuvant chemotherapy was 0.60, which is superior to the 4-year EFS of 0.37 reported by Schwartzberg et al. 21 In our series, the 21 patients with stage III disease who had inoperable tumors and were treated with neoadjuvant chemotherapy followed by surgery achieved an EFS at 3 and 5 years of 0.42 and were identified as having the worst prognosis of any group. The aggressive nature of the breast cancer in these patients was demonstrated by the high proportion of patients (95%) who, in spite of the neoadjuvant chemotherapy, had residual tumor and a median of five metastatic lymph nodes at the time of mastectomy. The presence of residual disease after neoadjuvant chemotherapy has been confirmed as an extremely poor prognostic factor. 44 However, in our study the univariate and the multivariate analyses did not identify differences in the impact of HDC/ASCI consolidation on survival or EFS when patients with stage III disease were analyzed according to the initial treatment received before transplantation. The multivariate analysis showed a trend for adverse outcome of patients with stage III inoperable tumors treated with neoadjuvant chemotherapy (risk ratio 1.939, CI 0.91-4.11 P = 0.08), but failed to identify other adverse prognostic factors as reported by Somlo et al 16 and Schwartzberg et al. 21 This fact could be explained in part by smaller numbers of patients with ER/PR negativity treated in our series. In both studies reported, the distribution of patients according to hormonal status was well balanced. In Somlo's study, 16 56% of patients were PR or ER positive while Schwartzberg et al 21 reported 55% and 40% of patients with ER/PR positive and ER/PR negative, respectively. In contrast, in the FHCRC/PSOC series, two-thirds (68%) of patients were ER or PR positive and one-third (26%) were ER and PR negative.
The role of HDC/ASCI as a feasible modality of treatment for high-risk breast cancer patients has been questioned in the context of negative results reported in two randomized trial, published in article form, 20, 22 and two preliminary reports published in abstract form 34, 35 comparing HDC to a control group. These ongoing phase III randomized studies evaluating HDC/ASCI as consolidation will need further follow-up and definitive results will not be available for at least 2-4 or more years. Since breast Bone Marrow Transplantation cancer is a heterogeneous disease, further studies are warranted to establish the role of HDC/ASCI in the treatment of these patients.
